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Table**How data were acquired**The vial containing the aqueous extract stand in the autosampler of the ELUTE system, automatically injected into an Ultra High Performance Liquid Chromatography (UHPLC), and the eluted compounds from the chromatographic column were introduced into the electrospray ion source of a Quadrupole Time-of-Flight mass spectrometer (QToF Impact II, Bruker). The data was acquired using the Data Analysis 4.4™ software, from Bruker.**Data format**Raw (Figure)\
Secondary data: obtained from raw data (Table)**Parameters for data collection**Mass spectrometer conditions: ion spray voltage, --3.5 kV; nebulizer gas (N~2~), 2.0 bars; dry gas (N~2~), 4.0 L.min^−1^; dry heater, 200 °C; collision cell energy, 5.0 eV; end plate offset, 500 V. The internal calibration was performed using the high-precision calibration mode (HPC) and a solution that consisted of 250 mL H~2~O, 250 mL iPrOH, 750 μL acetic acid, 250 μL formic acid and 0.5 mL 1N NaOH solution, introduced to the ion source via a 20 μL loop before the sample enter the mass spectrometer, through a six-port valve. Data acquisition was performed in full scan positive mode in the range of m/z 50--1500, acquisition rate of 1 Hz. The Auto MS/MS mode was used to confirm the fragment ions. The liquid chromatography mass spectrometry (LC-MS) acquisition data were processed using the Data Analysis 4.4™ software, to extract the mass spectral features from samples raw data. Chromatograms with the retention times for several compounds leaving the chromatographic column, with different exact masses, could be obtained and each mass peak fragmentation could be searched for.**Data source location**Lisbon/Portugal/BioISI (mass spectrometry facility)/Universidade de Lisboa. Faculdade de Ciências/Latitude 38^o^45'26.09'' N; Longitude 9^o^9'24.02''W.**Data accessibility**http://dx.doi.org/10.17632/y4g36252cm.1**Related research article**Authors' names\
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Bioactivities of Iridoids and flavonoids present in decoctions from aerial parts of Verbascum betonicifolium (under evaluation)

1. Value of the data {#sec0001}
====================

•These data give the experimental conditions for separation and identification of leaves' metabolites from plants aqueous extracts.•Researchers working on plant metabolites and practitioners of natural medicines may have a scientific base for the results obtained.•These data may be used by other researchers to compare secondary metabolites in plants of the same family, helping to find biomarkers between the species.

2. Data description {#sec0002}
===================

Data from analysis by LC-MS/MS of the aqueous extract of the areal part of *Verbascum betonicifolium* prepared as decoction, in the negative mode, is shown in [Fig 1](#fig0001){ref-type="fig"}.Fig. 1LC-MS chromatogram, in the negative mode, of the decoction from *Verbascum betonicifolium.*Fig 1

3. Experimental design, materials and methods {#sec0003}
=============================================

\[Offer a complete description of the experimental design and methods used to acquire these data. Please provide any programs or code files used for filtering and analyzing these data. It is very important

The 23 compounds indicated in [Fig 1](#fig0001){ref-type="fig"} were identified using the molecular formula suggested from the Data Analysis™ software and confirming by MS/MS analysis. The molecular formulas and the MS/MS fragments obtained for each proposed compound, as well its experimental mass and the respective error difference from the exact mass (ppm) are indicated in [Table 1](#tbl0001){ref-type="table"}. [Table 1](#tbl0001){ref-type="table"} also has a tentative drawing of the structures to give an insight into its molecular design. These structures will help to explain any enzyme inhibitory activity and the antioxidant activity that may be detected with this extract when the enzyme inhibitory activity whose active site structure is known [@bib0001] and will help to propose through docking studies which will be the most appropriate inhibitor for the enzyme under evaluation.Table 1Tentative identification of compounds present in mucilage-free extract by High Resolution Mass Spectrometry (HRMS), using LC--MS/MS, in the ESI negative mode.Table 1RT (min)\[M-H\]^−^FormulaError (ppm)MS/MS product ionsProposed compoundPutative structure11.1133.0144C~4~H~6~O~5~−1.3115 (10 %); 72 (84.2 %); 71 (100 %); 59 (27.5 %)malic acid![](fx1.gif)21.3195.0508C~6~H~12~O~7~1.189 (8.7 %); 87 (23 %); 85 (18.5 %); 75 (100 %); 72 (24 %); 71 (22.6 %); 59 (71.7 %); 57 (9.1%)gluconic acid![](fx2.gif)31.8191.0194C~6~H~8~O~7~1.8111 (77.3 %); 87 (100 %); 85 (30.7 %); 67 (7.1 %); 59 (15.2 %); 57 (28.1 %)citric acid![](fx3.gif)41.8217.0352C~8~H~10~O~7~0.0199 (2 %); 155 (6 %); 127 (13 %); 119 (8 %); 115 (30 %); 83 (100 %)6-*O*-acetylascorbic acid![](fx4.gif)51.9407.1195C~16~H~24~O~12~0.0181 (19 %); 163 (17 %); 151 (23 %); 113 (11 %)unedide![](fx5.gif)62.5391.1245C~16~H~24~O~11~0.2183 (23 %); 165 (26 %); 139 (14 %); 101(7%)shanzhiside![](fx6.gif)73.9409.1344C~16~H~26~O~12~1.8183 (100 %); 179 (25 %); 165 (44 %); 121(7%)glycoside derivative[a](#tb1fn1){ref-type="table-fn"}![](fx7.gif)84.1393.1401C~16~H~26~O~11~0.3175 (19 %); 127 (21 %); 132 (3 %); 113 (4 %)Methyl scutelloside![](fx8.gif)95.1353.0883C~16~H~18~O~9~−1.3191 (100 %)chlorogenic acid![](fx9.gif)105.7637.1028C~27~H~26~O~18~0.4461 (40.3 %); 285 (100 %)luteolin 7-glucuronosyl-(1-2) -glucuronide![](fx10.gif)115.8621.1091C~27~H~26~O~17~1.0445 (41%); 269 (100%)apigenin 7-glucuronosyl- (1-2)-glucuronside![](fx11.gif)126.1669.2031C~30~H~38~O~17~0.1354 (1 %); 325 (3.4 %); 179 (8 %); 161 (55 %); 135 (31 %)taxifolin derivative[b](#tb1fn2){ref-type="table-fn"}![](fx12.gif)136.5623.1997C~29~H~36~O~15~−2.4623 (40.5 %); 461 (11.7 %); 161 (100 %); 133 (33.7 %)verbascoside![](fx13.gif)146.6447.0932C~21~H~20~O~11~0.2447 (32.1 %); 285 (100 %); 284 (31 %); 227 (16 %); 201 (10.6 %); 133 (10.3 %); 107 (14.3 %)luteolin 7-O-glucoside![](fx14.gif)156.6461.0722C~21~H~18~O~12~0.7285 (100 %); 133 (16.6 %)luteolin 7-O-glucuronide![](fx15.gif)166.6653.2082C~30~H~38~O~16~0.8653 (100 %); 377 (39.4 %); 309 (11.3 %); 163 (74.6 %); 145 (89.6 %); 119 (52.5 %); 117 (23.7 %)saccatoside![](fx16.gif)176.7401.1819C~19~H~30~O~9~1.0221 (15 %); 195 (1 %); 162 (1 %); 71 (28 %); 59 (47 %)sauroposide![](fx17.gif)186.8683.2154C~31~H~40~O~17~5.6407 (41 %); 193 (60 %); 163 (11 %); 160 (65 %); 149 (9 %)Scropheanosi de II![](fx18.gif)197.1431.0981C~21~H~20~O~10~0.7-apigenin 7-O-glucoside![](fx19.gif)207.2445.0770C~21~H~18~O~11~1.4269 (100 %); 117 (16.3 %)apigenin 7-galactoronide![](fx20.gif)218.4285.0398C~15~H~10~O~6~2.2285 (100 %); 217 (9.1 %); 201 (6.7 %); 199 (11.3 %); 175 (10.8 %); 151 (15.9 %); 149 (7.3 %); 133 (41.4 %); 132 (12.4 %);luteolin![](fx21.gif)229.2269.0456C~15~H~10~O~5~−0.2269 (100 %); 227 (31.9 %); 165 (19.7%); 159 (6.9 %); 151 (70.6%); 149 (34.6 %); 117 (60.8 %); 107 (24.3 %);apigenin![](fx22.gif)2311.7293.1759C~17~H~26~O~4~0.2236 (28 %); 221 (100 %)phytuberin![](fx23.gif)[^1][^2]

4. Experimental design, materials and methods {#sec0004}
=============================================

The plant was collected in Algeria and prepared according to the process described in [@bib0001]. After filtration of the decoction, the aqueous extract was lyophilized, and a powder was obtained. For LC-MS/MS analysis, 1 mg was dissolved in MiliQ water (Millipore) and the vial was introduced in the autosampler. A chromatographic column Intensity Solo 2 RP-18, 100 × 2.1 mm, 2.0 µm column (Bruker, Bremen, Germany) was used. The elution conditions were described in [@bib0001], briefly: 5 µL were injected (auto injector) and a flow rate of 0.250 mL/min for the elution was used. The column was kept at 35°C and the samples at 10°C. The eluting gradient was composed of gradient of water with 0.1% formic acid (eluent A) and acetonitrile with 0.1% formic acid (eluent B) as follows: 0 min -- 95% A; 1.5 min -- 95% A; 13.5 min -- 25% A; 18.5 min -- 0% A; 21.5 min -- 0% A; 23.5 min -- 95% A; 30 min -- 95% A. The chromatographic equipment was an ELUTE autosampler (UHPLC) from Bruker (Bremen, Germany) coupled to an Ultra-High-Resolution Quadrupole Time-of-Flight mass spectrometer (UHR-QToF, Impact II) also from Bruker (Bremen, Germany). The mass analysis was carried out with the parameters indicated in [@bib0002], briefly: the mass spectrometer was operated in the negative mode with the following parameters: ion spray voltage, --3.5 kV; nebulizer gas (N~2~), 2.0 bars; dry gas (N~2~), 8.0 L.min^−1^; dry heater, 200 °C; collision cell energy, 5.0 eV; end plate offset, 500 V. Calibration of masses was done by internal calibration method using a solution that consisted of 250 mL H~2~O, 250 mL iPrOH, 750 μL acetic acid, 250 μL formic acid and 0.5 mL 1N NaOH solution, on the HPC mode. The calibration solution was introduced into the ion source via a 20 μL loop, before the sample enter the mass spectrometer, through a six-port valve. The acquisition was performed in full scan mode in the 50--1500 m/z range, with an acquisition rate of 1 Hz. The Auto MS/MS mode was used to confirm the fragment ions. The LC-MS acquired data were processed using Data Analysis 4.4™ software (Bruker) to extract the mass spectral features from the sample raw data. The suggestion of chemical formulas according to the exact mass was done using the Data Analysis™ software. These suggestions were verified using online search in the databases Metlin (https://metlin.scripps.edu/landing_page.php?pgcontent=mainPage), in the simple search mode, and PubChem (https://pubchem.ncbi.nlm.nih.gov/) and confirmed through MS/MS analyses. For this analysis, the «Fragmentation Explorer» from Data Analysis™ software was used.
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[^1]: : 1-\[(2*R*,3*R*,4*S*,5*S*,6*R*)-2-\[(3*S*,4*S*,5*R*)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl\]oxy-3,4,5-trihydroxy-6-(hydroxymethyl)-3-methyloxan-2-yl\]prop-2-en-1-one

[^2]: : 5-Hydroxy-7-(2-hydroxyethoxy)-2-(3-hydroxy-4-methoxyphenyl)-3-\[(2R,3S,4R,5R,6S)-3,4,5-trihydroxy-6-\[\[(2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl\]oxymethyl\]oxan-2-yl\]oxy-2,3-dihydrochromen-4-one
